References
- Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann. 2014;45:301–314.
- Montouchet C, Trussell J. Unintended pregnancies in England in 2010: costs to the National Health Service (NHS). Contraception. 2013;87:149–153.
- Finer LB, Zolna MR. Shifts in intended and unintended pregnancies in the United States, 2001–2008. Am J Public Health. 2014;104:S43–S48.
- Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Vital Health Stat. 2010;23:1–44.
- Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.
- National Institute for Health and Care Excellence. Long-acting reversible contraception (LARC) [Internet]. 2005 [cited 2016 Feb 4]. Available from: https://www.nice.org.uk/guidance/cg30.
- World Health Organization. Medical eligibility criteria for contraceptive use: fifth edition [Internet]. Geneva: World Health Organization; 2015 [cited 2016 Feb 4]. Available from: http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/.
- Heinemann K, Reed S, Moehner S, et al. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception. 2015;91:280–283.
- Bayer HealthCare Pharmaceuticals Inc. Jaydess® summary of product characteristics [Internet]. 2015 [cited 2016 Feb 4]. Available from: http://www.medicines.org.uk/emc/medicine/28672.
- Nelson AL, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013;122:1205–1213.
- Suhonen S, Haukkamaa M, Jakobsson T, et al. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004;69:407–412.
- Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986;34:253–260.
- Colonna L, Pacifico V, Lello S, et al. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. J Eur Acad Dermatol Venereol. 2012;26:1364–1371.
- Bayer HealthCare Pharmaceuticals. Yasmin® Prescribing Information. [Internet] 2014 [cited 2016 Feb 4]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf.
- Bayer HealthCare Pharmaceuticals Inc. Microgynon® 30 ED Prescribing Information. [Internet] 2014 [cited 2016 Feb 4]. Available from: http://www.bayerresources.com.au/resources/uploads/pi/file9391.pdf.
- O'Neil-Callahan M, Peipert JF, Zhao Q, et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol. 2013;122:1083–1091.
- Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117:1105–1113.
- Stephenson J, Shawe J, Panicker S, et al. Randomized trial of the effect of tailored versus standard use of the combined oral contraceptive pill on continuation rates at 1 year. Contraception. 2013;88:523–531.
- Berenson AB, Rahman M. A randomized controlled study of two educational interventions on adherence with oral contraceptives and condoms. Contraception. 2012;86:716–724.
- Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366:1998–2007.
- Sanders SA, Graham CA, Bass JL, et al. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64:51–58.
- Lete I, Perez-Campos E, Correa M, et al. Continuation rate of combined hormonal contraception: a prospective multicenter study. J Womens Health (Larchmt). 2012;21:490–495.